| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 7 analysts have evaluated Avidity Biosciences (NASDAQ:RNA), offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $37.29, along with a high estimate of $60.00 and a low estimate of $23.00. This upward trend is evident, with the current average reflecting a 62.13% increase from the previous average price target of $23.00.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Avidity Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Geoff Meacham | B of A Securities | Announces | Buy | $40.00 | - |
| Joseph Stringer | Needham | Maintains | Buy | $35.00 | - |
| Eric Schmidt | Cantor Fitzgerald | Announces | Overweight | $60.00 | - |
| Keay Nakae | Chardan Capital | Raises | Buy | $33.00 | $23.00 |
| Joseph Stringer | Needham | Maintains | Buy | $35.00 | - |
| Joseph Stringer | Needham | Maintains | Buy | $35.00 | - |
| Keay Nakae | Chardan Capital | Maintains | Buy | $23.00 | - |
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Avidity Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on Avidity Biosciences analyst ratings.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Avidity Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2023, the company experienced a revenue decline of approximately -20.8%. This indicates a decrease in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Avidity Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2756.18% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Avidity Biosciences's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -11.87%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Avidity Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.06%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Avidity Biosciences's debt-to-equity ratio is below the industry average at 0.02, reflecting a lower dependency on debt financing and a more conservative financial approach.
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RNA
